QQQ   315.68 (+0.95%)
AAPL   162.36 (+0.99%)
MSFT   284.05 (+1.26%)
META   207.84 (+1.21%)
GOOGL   100.89 (-0.49%)
AMZN   102.00 (+1.75%)
TSLA   195.28 (+0.72%)
NVDA   273.83 (+1.48%)
NIO   10.46 (+6.41%)
BABA   103.38 (+3.46%)
AMD   97.88 (+1.86%)
T   19.08 (+0.42%)
F   12.29 (+1.99%)
MU   63.09 (-0.71%)
CGC   1.76 (-2.76%)
GE   94.05 (-0.01%)
DIS   98.10 (+1.27%)
AMC   4.97 (-0.60%)
PFE   40.38 (+0.32%)
PYPL   74.39 (+0.28%)
NFLX   338.43 (+1.93%)
QQQ   315.68 (+0.95%)
AAPL   162.36 (+0.99%)
MSFT   284.05 (+1.26%)
META   207.84 (+1.21%)
GOOGL   100.89 (-0.49%)
AMZN   102.00 (+1.75%)
TSLA   195.28 (+0.72%)
NVDA   273.83 (+1.48%)
NIO   10.46 (+6.41%)
BABA   103.38 (+3.46%)
AMD   97.88 (+1.86%)
T   19.08 (+0.42%)
F   12.29 (+1.99%)
MU   63.09 (-0.71%)
CGC   1.76 (-2.76%)
GE   94.05 (-0.01%)
DIS   98.10 (+1.27%)
AMC   4.97 (-0.60%)
PFE   40.38 (+0.32%)
PYPL   74.39 (+0.28%)
NFLX   338.43 (+1.93%)
QQQ   315.68 (+0.95%)
AAPL   162.36 (+0.99%)
MSFT   284.05 (+1.26%)
META   207.84 (+1.21%)
GOOGL   100.89 (-0.49%)
AMZN   102.00 (+1.75%)
TSLA   195.28 (+0.72%)
NVDA   273.83 (+1.48%)
NIO   10.46 (+6.41%)
BABA   103.38 (+3.46%)
AMD   97.88 (+1.86%)
T   19.08 (+0.42%)
F   12.29 (+1.99%)
MU   63.09 (-0.71%)
CGC   1.76 (-2.76%)
GE   94.05 (-0.01%)
DIS   98.10 (+1.27%)
AMC   4.97 (-0.60%)
PFE   40.38 (+0.32%)
PYPL   74.39 (+0.28%)
NFLX   338.43 (+1.93%)
QQQ   315.68 (+0.95%)
AAPL   162.36 (+0.99%)
MSFT   284.05 (+1.26%)
META   207.84 (+1.21%)
GOOGL   100.89 (-0.49%)
AMZN   102.00 (+1.75%)
TSLA   195.28 (+0.72%)
NVDA   273.83 (+1.48%)
NIO   10.46 (+6.41%)
BABA   103.38 (+3.46%)
AMD   97.88 (+1.86%)
T   19.08 (+0.42%)
F   12.29 (+1.99%)
MU   63.09 (-0.71%)
CGC   1.76 (-2.76%)
GE   94.05 (-0.01%)
DIS   98.10 (+1.27%)
AMC   4.97 (-0.60%)
PFE   40.38 (+0.32%)
PYPL   74.39 (+0.28%)
NFLX   338.43 (+1.93%)
NASDAQ:GNOM

Global X Genomics & Biotechnology ETF - GNOM Stock Forecast, Price & News

$11.92
-0.08 (-0.68%)
(As of 03/30/2023 12:00 AM ET)
Add
Today's Range
$11.82
▼
$12.13
50-Day Range
$11.73
▼
$14.18
52-Week Range
$10.48
▼
$16.75
Volume
37,421 shs
Average Volume
78,420 shs
Market Capitalization
$200.02 million
P/E Ratio
N/A
Dividend Yield
0.00%
Price Target
N/A

Global X Genomics & Biotechnology ETF MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
0.26% of Shares Sold Short
Dividend Strength
Weak
Based on Four Factors
Sustainability
N/A
News Sentiment
0.44mentions of Global X Genomics & Biotechnology ETF in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

0.96 out of 5 stars

See Top Rated MarketRank™ Stocks Here

GNOM stock logo

About Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) Stock

Complete Genomics, Inc. is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research. Its genome sequencing center combines a high-throughput sample preparation facility, a collection of its high-throughput sequencing instruments and a large- scale data center. Its customers include some of the global academic and government research centers and biopharmaceutical companies. Effective March 18, 2013, BGI-Shenzhen announced that through its wholly-owned subsidiary, Beta Acquisition Corporation, it has completed the acquisition of the Company.

Receive GNOM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Global X Genomics & Biotechnology ETF and its competitors with MarketBeat's FREE daily newsletter.

GNOM Stock News Headlines

February 16, 2023 | benzinga.com
Global X Adaptive U.S. Risk Management ETF (ONOF): January 2023 Report
January 18, 2023 | seekingalpha.com
GNOM: Get Exposure To The Latest Genomics And Biotechnology Companies
March 30, 2023 | Weiss Ratings (Ad)
Bank Accounts: Frozen!
In 1990, the Brazilian government froze the bank accounts of thousands of citizens. In 2013, the victims were the people of Cyprus. In 2022, it hit closer to home — in Canada. And now the Federal Reserve System Docket No. OP-1670 reveals the plan to give the Fed the power to track and potentially even control your checking account. Not just the money you have in your account … But also, every single check, withdrawal, deposit and transaction. Practically everything you do with your money!
January 10, 2023 | markets.businessinsider.com
Complete Genomics Launches Full Sequencing Platforms at Biotech Showcase™ 2023
January 6, 2023 | benzinga.com
Global X Adaptive U.S. Risk Management ETF (ONOF): November Report
October 12, 2022 | seekingalpha.com
10x Genomics: No Signs Of A Growth Turnaround, Heavy Bearish Momentum
July 15, 2022 | benzinga.com
What 5 Analyst Ratings Have To Say About 10x Genomics
June 16, 2022 | benzinga.com
NIH's National Human Genome Research Institute and NSTA Unveil New Genome: Unlocking Life's Code Educational Resources for Educators
March 30, 2023 | Weiss Ratings (Ad)
Bank Accounts: Frozen!
In 1990, the Brazilian government froze the bank accounts of thousands of citizens. In 2013, the victims were the people of Cyprus. In 2022, it hit closer to home — in Canada. And now the Federal Reserve System Docket No. OP-1670 reveals the plan to give the Fed the power to track and potentially even control your checking account. Not just the money you have in your account … But also, every single check, withdrawal, deposit and transaction. Practically everything you do with your money!
June 6, 2022 | markets.businessinsider.com
Ultima Genomics Collaborates with NVIDIA To Deliver $100 Genome Sequencing with AI and Accelerated Computing
December 29, 2021 | msn.com
Is ARK's Stellar Run Over? 5 ETF Themes to Follow Cathie Wood
December 22, 2021 | nasdaq.com
Get Exposure to Global X Thematic ETFs in This One Fund
July 16, 2021 | nasdaq.com
Snag Next-Generation Tech Exposure with This Genomics ETF
June 4, 2021 | msn.com
ETF Battles: ARKG vs. GNOM - Which Is The Better Genomics/Biotech Play?
December 29, 2020 | msn.com
Top-Performing Biotech ETFs Amid the COVID-19 Crisis
December 24, 2020 | msn.com
4 Best Sector ETFs of Q4
December 23, 2020 | nasdaq.com
Get On Board a Growing Biotech Industry With the GNOM ETF
November 26, 2020 | barrons.com
Global X Genomics & Biotechnology ETF
November 25, 2020 | finance.yahoo.com
ETF Wrap: A very ETF Thanksgiving, and tax season too
October 18, 2020 | nasdaq.com
Global X Genomics & Biotechnology ETF (GNOM)
October 15, 2020 | msn.com
Why You Should Invest in Genomics ETFs
June 18, 2020 | www.nasdaq.com
Biotechnology Is Hot, But It's Getting Scorching in This Segment
May 26, 2020 | www.msn.com
3 Genomics ETFs Worth Jumping For
May 26, 2020 | finance.yahoo.com
Genomics ETF (GNOM) Hits New 52-Week High
March 28, 2020 | markets.businessinsider.com
The single cell sequencing industry analysis projects the market to grow at a significant CAGR of 15.24% during the forecast period, 2019-2029
March 20, 2020 | www.marketwatch.com
Micro Electro Mechanical Systems Market Emerging Opportunities, Growing Demand and Significant Trends by 2027
March 19, 2020 | www.msn.com
6 stocks that rose despite the coronavirus sell-off
See More Headlines
Receive GNOM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Global X Genomics & Biotechnology ETF and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
N/A
Sub-Industry
N/A
Sector
N/A
Current Symbol
NASDAQ:GNOM
CUSIP
N/A
CIK
1361103
Web
www.completegenomics.com
Phone
+1-650-9432800
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
16,780,000
Free Float
N/A
Market Cap
$201.70 million
Optionable
Not Optionable
Beta
1.02














GNOM Stock - Frequently Asked Questions

How have GNOM shares performed in 2023?

Global X Genomics & Biotechnology ETF's stock was trading at $12.65 at the beginning of 2023. Since then, GNOM shares have decreased by 5.0% and is now trading at $12.02.
View the best growth stocks for 2023 here.

Are investors shorting Global X Genomics & Biotechnology ETF?

Global X Genomics & Biotechnology ETF saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 42,900 shares, an increase of 29.2% from the February 28th total of 33,200 shares. Based on an average daily trading volume, of 85,700 shares, the short-interest ratio is presently 0.5 days.
View Global X Genomics & Biotechnology ETF's Short Interest.

What ETFs hold Global X Genomics & Biotechnology ETF's stock?

ETFs with the largest weight of Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) stock in their portfolio include Global X Thematic Growth ETF (GXTG).

What other stocks do shareholders of Global X Genomics & Biotechnology ETF own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Global X Genomics & Biotechnology ETF investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Sanofi (SNY), Intel (INTC), Pfizer (PFE), Quest Diagnostics (DGX), Micron Technology (MU), Dynavax Technologies (DVAX), Matinas BioPharma (MTNB).

What is Global X Genomics & Biotechnology ETF's stock symbol?

Global X Genomics & Biotechnology ETF trades on the NASDAQ under the ticker symbol "GNOM."

Who are Global X Genomics & Biotechnology ETF's major shareholders?

Global X Genomics & Biotechnology ETF's stock is owned by a number of retail and institutional investors. Top institutional investors include Northwestern Mutual Wealth Management Co. (39.88%), Private Advisor Group LLC (6.47%), Mirae Asset Global Investments Co. Ltd. (3.01%), One Capital Management LLC (2.66%), McGuire Investment Group LLC (1.50%) and Portland Global Advisors LLC (1.29%).

How do I buy shares of Global X Genomics & Biotechnology ETF?

Shares of GNOM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Global X Genomics & Biotechnology ETF's stock price today?

One share of GNOM stock can currently be purchased for approximately $12.02.

How much money does Global X Genomics & Biotechnology ETF make?

Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) has a market capitalization of $201.70 million.

How can I contact Global X Genomics & Biotechnology ETF?

Global X Genomics & Biotechnology ETF's mailing address is 2071 Stierlin Ct, MOUNTAIN VIEW, CA 94043-4655, United States. The official website for the company is www.completegenomics.com. The company can be reached via phone at +1-650-9432800.

This page (NASDAQ:GNOM) was last updated on 3/30/2023 by MarketBeat.com Staff